Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
63°
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
Photos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Entrada Therapeutics, Inc.
Entrada Therapeutics Announces First Participant Dosed in its Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne Muscular Dystrophy
September 21, 2023
From
Entrada Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TRDA
Entrada Therapeutics Awards Funding to Non-Profit Organizations Advancing Diversity, Equity, Inclusion and Accessibility within the Duchenne Muscular Dystrophy Community
September 07, 2023
From
Entrada Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TRDA
Entrada Therapeutics to Present at Upcoming Investor Conferences
August 29, 2023
From
Entrada Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TRDA
Entrada Therapeutics Appoints Gina Chapman to its Board of Directors
August 10, 2023
From
Entrada Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TRDA
Entrada Therapeutics Reports Second Quarter 2023 Financial Results
August 08, 2023
From
Entrada Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TRDA
Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne Muscular Dystrophy
August 01, 2023
From
Entrada Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TRDA
Entrada Therapeutics to Present at Goldman Sachs 44th Annual Global Healthcare Conference
June 06, 2023
From
Entrada Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TRDA
Entrada Therapeutics Reports First Quarter 2023 Financial Results
May 10, 2023
From
Entrada Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TRDA
Entrada Therapeutics Appoints Dr. Bernhardt Zeiher to its Board of Directors
April 04, 2023
From
Entrada Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TRDA
Entrada Therapeutics to Participate in Guggenheim Genomic Medicines and Rare Disease Conference
March 29, 2023
From
Entrada Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TRDA
Entrada Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
March 06, 2023
From
Entrada Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TRDA
Entrada Therapeutics to Participate in Cowen 43rd Annual Health Care Conference
February 27, 2023
From
Entrada Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TRDA
Entrada Therapeutics Closes Agreement with Vertex to Discover and Develop Endosomal Escape Vehicle-Therapeutics for Myotonic Dystrophy Type 1 (DM1)
February 09, 2023
From
Entrada Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TRDA
Entrada Therapeutics Announces Clinical Candidate, ENTR-601-45, for the Potential Treatment of People Living with Duchenne Muscular Dystrophy who are Exon 45 Skipping Amenable
January 09, 2023
From
Entrada Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TRDA
Entrada Therapeutics Announces Clinical Hold on IND Application for ENTR-601-44 in Duchenne Muscular Dystrophy
December 19, 2022
From
Entrada Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TRDA
Entrada Therapeutics to Present at Evercore ISI 5th Annual HealthCONx Virtual Conference
November 22, 2022
From
Entrada Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TRDA
Entrada Therapeutics Reports Third Quarter 2022 Financial Results
November 07, 2022
From
Entrada Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TRDA
Entrada Therapeutics Appoints Biotech Industry Leader Mary Thistle to Its Board of Directors
May 04, 2021
From
Entrada Therapeutics, Inc.
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.